Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | TEAD4 | Q15561 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | TEAD1 | P28347 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | TEAD2 | Q15562 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pirlindole SCHEMBL29500947 | 1.00 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL18877133 | 1.00 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL18878061 | 1.00 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL4157397 | 0.99 | HSD17B10 (0.97) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL1649683 | 0.97 | HSD17B10 (0.95) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL4152460 | 0.94 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL30984462 | 0.92 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL3761340 | 0.92 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL17241165 | 0.83 | HSD17B10 (0.68) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL13702963 | 0.82 | KMT2A (0.98) | HSD17B10MEN1KMT2AKDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2208 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | Natural MedTech Pty Ltd (AU) | 2025-11-06 | — | — | US | claimed |
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4615444-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural Medtech Pty Ltd (AU) | 2025-09-17 | — | — | EP | claimed |
| US-12396982-B2 | Compositions of matter and pharmaceutical compositions | ATAI THERAPEUTICS, INC. (US) | 2025-08-26 | — | — | US | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250041273-A1 | NOVEL COMPOSITIONS OF MATTER AND PHARMACEUTICAL COMPOSITIONS | ATAI LIFE SCIENCES N.V. (DE) | 2025-02-06 | — | — | US | claimed |
| EP-4479032-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | Sage Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | claimed |
| US-20240408059-A1 | METHOD OF TREATING ADDICTION | ANEBULO PHARMACEUTICALS, INC. | 2024-12-12 | — | — | US | claimed |
| EP-1210080-A2 | USE OF MONOAMINE OXIDASE INHIBITORS FOR THE MANUFACTURE OF DRUGS INTENDED FOR THE TREATMENT OF OBESITY | Sanofi-Aventis (FR) | 2002-06-05 | — | — | EP | claimed |
| WO-2002041883-A2 | AS-NEEDED ADMINISTRATION OF TRICYCLIC AND OTHER NON-SRI ANTIDEPRESSANT DRUGS TO TREAT PREMATURE EJACULATION | VIVUS, INC. (US) | 2002-05-30 | — | — | WO | claimed |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | VIVUS, INC. | 2002-03-28 | — | — | US | claimed |
| EP-1150715-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE OR A LIGAND OF NICOTINE RECEPTORS AND A MONAMINE OXYDASE INHIBITOR AND THEIR USE FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | SANOFI-SYNTHELABO (FR) | 2001-11-07 | — | — | EP | claimed |
| US-20010008896-A1 | Administration of active agents, including 5-HT receptor agonists and antagonists, to treat premature ejaculation | SMITH WILLIAM L (US) | 2001-07-19 | — | — | US | claimed |
| EP-1078632-A1 | Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity | SANOFI-SYNTHELABO (FR) | 2001-02-28 | — | — | EP | claimed |
| WO-2001012176-A2 | USE OF MONOAMINE OXIDASE INHIBITORS FOR THE MANUFACTURE OF DRUGS INTENDED FOR THE TREATMENT OF OBESITY | SANOFI-SYNTHELABO (FR) | 2001-02-22 | — | — | WO | claimed |
| WO-2000045846-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE OR A LIGAND OF NICOTINE RECEPTORS AND A MONAMINE OXYDASE INHIBITOR AND THEIR USE FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | SANOFI-SYNTHELABO (FR) | 2000-08-10 | — | — | WO | claimed |
| US-5922341-A | Local administration of pharmacologically active agents to treat premature ejaculation | VIVUS, INCORPORATED (US) | 1999-07-13 | — | — | US | claimed |
| WO-1999013879-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A MONOAMINE OXYDASE INHIBITOR AND THEIR USE IN THERAPY | SANOFI-SYNTHELABO (FR) | 1999-03-25 | — | — | WO | claimed |